50680

status/Pages/status.aspx. The NIH is required by the BPCA to update the priority list every three years. This publication serves as an update to the BPCA priority list of needs in pediatric therapeutics.

The Obstetric and Pediatric Pharmacology and Therapeutics Branch of the NICHD developed a prioritization process for the determination of the needs in pediatric therapeutics. There are two main phases in this process. Phase I of the prioritization process entails identifying therapeutic areas, which are general categories of conditions, diseases, settings of care, or populations with multiple therapeutic needs. The NICHD solicits input from experts in the pediatric research, general pediatric and subspecialty care, and patient advocacy groups to determine these therapeutic areas that need further study. At the beginning of every year, the NICHD revisits the current list of needs in pediatric therapeutics, prioritizes three therapeutic areas of interest for that calendar year, and develops working groups in the prioritized areas. Recommendations from the therapeutic area working groups are then presented to the NICHD and the FDA at the end of the calendar year at the Institute's annual BPCA meeting. Previous meeting minutes can be found on the BPCA Web site: http://bpca.nichd.nih.gov/prioritization/ meetings/Pages/index.aspx.

Phase II of the prioritization process entails an extensive review and ranking of all nominations received based on key criteria for prioritization, such as relevance, label gaps, affected population, and feasibility. Please visit the BPCA Web site for more details: (http://bpca.nichd.nih.gov/ prioritization/priority_list/Pages/ priority_list.aspx).

Below is an updated list of therapeutic areas and drugs that have been prioritized for study since the inception of the BPCA and a summary of the NICHD's plans and progress in all of these areas to date. The NICHD welcomes input from the pediatric medical community on additional gaps in pediatric therapeutics for future consideration. All nominations should be submitted to Dr. Perdita Taylor-Zapata (contact information below).

Priority List of Needs in Pediatric Therapeutics 2014

In accordance with the BPCA legislation, the list outlines priority needs in pediatric therapeutics for multiple therapeutic areas listed below. The complete list can be found on the BPCA Web site at the following address: http://bpca.nichd.nih.gov.

- Table 1: Infectious Disease Priorities
- Table 2: Cardiovascular Disease Priorities
- Table 3: Respiratory Disease Priorities
- Table 4: Intensive Care Priorities
- Table 5: Bio-Defense Research Priorities
- Table 6: Pediatric Cancer Priorities
- Table 7: Psychiatric Disorder Priorities
- Table 8: Neurological Disease
 Priorities
- Table 9: Neonatal Research Priorities
- Table 10: Adolescent Research Priorities
- Table 11: Hematologic Disease
 Priorities
- Table 12: Endocrine Disease Priorities and Diseases With Limited Alternative Therapies
- Table 13: Dermatologic Disease
 Priorities
- Table 14: Gastrointestinal Disease Priorities
- Table 15: Renal Disease Priorities
- Table 16: Rheumatologic Disease
 Priorities
- Table 17: Special Considerations We would like for you to save the date of December 10, 2014, for our annual BPCA stakeholders meeting. The meeting will be held at the Natcher Auditorium on the NIH campus in Bethesda, Maryland, and will be streamed live via videocast for all nonlocal attendees.

FOR FURTHER INFORMATION CONTACT: Dr. Perdita Taylor-Zapata via email at *taylorpe@mail.nih.gov;* by phone at 301–496–9584; or by fax at 301–480–2897.

Dated: August 18, 2014.

Francis S. Collins,

Director, National Institutes of Health. [FR Doc. 2014–20156 Filed 8–22–14; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases Cancellation of Meeting

Notice is hereby given of the cancellation of the National Institute of Allergy and Infectious Diseases Special Emphasis Panel, September 10, 2014, 10:00 a.m. to September 10, 2014, 12:00 p.m., National Institutes of Health, 6700B Rockledge Drive, Room 3124, Bethesda, MD 20817 which was published in the **Federal Register** on August 15, 2014, 79FR48173.

The Review Committee will not meet because the application was withdrawn.

Dated: August 19, 2014. **David Clary**, *Program Analyst, Office of Federal Advisory Committee Policy.* [FR Doc. 2014–20057 Filed 8–22–14; 8:45 am] **BILLING CODE 4140–01–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Ancillary Studies to the NIDDK IBDGC.

Date: October 16, 2014.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

¹*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Dianne Camp, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 756, 6707, Democracy Boulevard, Bethesda, MD 20892–2542, 301–594–7682, campd@extra.niddk.nih.gov.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, Small Grants for New Investigators to Promote Diversity.

Date: October 30, 2014.

Time: 12:00 p.m. to 2:30 p.m. *Agenda:* To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Barbara A. Woynarowska, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 754, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 402–7172, woynarowskab@niddk.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes,